Latvijas Juras medicinas centrs

Quarterly Report • May 25, 2018

JOINT STOCK COMPANY "LATVIJAS JŪRAS MEDICĪNAS CENTRS"

(Unified registration number: 40003306807)

FINANCIAL STATEMENTS FOR THE 3 MONTH OF 2018 (15 th financial year)

PREPARED IN ACCORDANCE WITH THE 'ANNUAL REPORTS AND CONSOLIDATED ANNUAL REPORT LAW' OF THE REPUBLIC OF LATVIA

Riga, 2018

AS Latvijas Jūras medicīnas centrs Address: Patversmes iela 23, Riga, LV-1005 Unified registration number: 40003306807

Contents

Information on the Company	3
Statement of the Board's Responsibility	4
Management Report	5 – 7
Financial statements:
Profit and Loss Statement	8
Balance Sheet	9 – 10
Statement of Changes to the Shareholders' Equity	11
Statement of Cash Flows	12
Notes to the Financial Statements	13 – 30

Information on the Company

Name of the Company	Latvijas Jūas medicīnas centrs
Legal status	Joint Stock Company
Number, place and date of registration	40003306807 Riga, 27 August 1996
	Re-registered with the Commercial Register 4000 330 6807	On 27 February 2004 under the unified registration number
Core business:	Hospital activities (86.10) stores (47.74) Other education n.e.c. (85.59) General medical practice activities (86.21) Special medical practice activities (86.22) Dental practice activities (86.23) Other human health activities (86.90) Residential nursing care activities (87.10) Other residential care activities (87.90) (88.99) Physical well-being activities (96.04) Other personal service activities n.e.c. (96.09)	Retail sale of medical and orthopaedic goods in specialised Other social work activities without accommodation n.e.c.
Legal address	Patversmes iela 23 Riga, LV-1005 Latvia
Largest shareholders	Ilze Birka (17.50%) Mārtiņš Birks (17.50%) Ilze Aizsilniece (8.82%) Guna Švarcberga (10.36%) Jānis Birks (12.80%) Adomas Navickas (6.85%)
Names of the Board members, their positions Names of the Council members, their positions	Jānis Birks – Chairman of the Board Juris Imaks – Member of the Board Anatolijs Ahmetovs - Member of the Board, since 13.01.2017 Mārtiņš Birks – Chairman of the Council Viesturs Šiliņš – Deputy Chairman of the Council Ineta Gadzjus – Member of the Council
	Jevgeņijs Kalējs – Member of the Council Uldis Osis – Member of the Council
Reporting period	1 January 2018 – 31 March 2018
Name and address of the certified auditor in charge	KPMG Baltics SIA Licence No.55 Vesetas iela 7 Riga, LV-1013 Latvia	Certified auditor in charge: Armine Movsisjana Certificate No. 178

Statement of the Board's Responsibility

The Board of AS Latvijas Jūras Medicīnas Centrs (hereinafter – the Company) is responsible for preparing the financial statements of the Company.

The financial statement on pages 8 to 30 is prepared based on accounting records and source documents and present fairly the financial position of LJMC as at 31 March 2018 and the results of its operations, and cash flows for the 3-month period of 2018.

The above mentioned financial statement of the Company is prepared in accordance with the laws 'On accounting' and 'Annual Reports and Consolidated Annual Reports Law' effective in the Republic of Latvia, on a going concern basis. Appropriate accounting policies have been applied on a consistent basis. Prudent and reasonable judgements and estimates have been made by the Management in the preparation of the financial statement.

The management of the Company is responsible for the maintenance of a proper accounting system, safeguarding the Company's assets, and the prevention and detection of fraud and other irregularities in the Company. The management is also responsible for compliance with laws of the Republic of Latvia.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

Management Report

Line of business

A/S Latvijas Jūras medicīnas centrs (LJMC or the Company) is a certified and advanced private medical facility available to everyone, which consists of Sarkandaugava Ambulatory Healthcare Centre at 23 Patversmes iela, Riga; Central Hospital at 23 Patversmes iela, Riga; Vecmilgravis Hospital and Northern Diagnostics Centre 26 Vecmilgravja 5.linija; Riga, and Vecmīlgrāvis Primary Health Care Centre at 10 Melidas iela, Riga. In 2017, the average number of employees of LJMC was 343. The shares of A/S Latvijas Jūras medicīnas centrs are traded on the Baltic Secondary list of Nasdaq Riga.

As of 5 September 2013, A/S Latvijas Jūras medicīnas centrs has been included on the list of medical facilities approved by the Health Inspectorate of Latvia, which provides medical tourism services, namely, LJMC provides medical tourism services as a reliable partner and this provides an insight into the overall Latvian health care system because the list only includes those healthcare institutions which have been registered with the register of health care institutions for at least 3 years and control has been carried out in the health care institution during the past three years.

In 2013, LJMC Northern Diagnostics Centre received from DNV Certification OY/AB Finland quality certificate ISO 9001:2008 in functional diagnostics and radiology diagnostics valid until 14 March 2016. This certificate was renewed at the beginning of 2016 to be valid until 15 September 2018. In 2017, LJMC will continue working on implementing ISO quality standards in other structural units of the centre.

LJMC has accredited Clinical Diagnostics Laboratory at 23 Patversmes iela with the Latvian National Accreditation Bureau.

LJMC has signed cooperation agreements with all health insurance companies operating in Latvia.

LJMC has received certificate No. 065 issued by Exova BM TRADA confirming the compliance of the energy management system with ISO 50001:2011 requirements.

Activities in the 12 months of 2017 and further development

The Company's activities in the 12 months of 2017

In 2017 LJMC continued to provide high-quality medical services and attract new local and foreign patients. Similar to prior years, also in 2017 LJMC employed excellent doctors from Latvia and competent medical personnel. Activities of highly qualified and professional personnel allowed LJMC to provide examinations of competitive and exceptional quality, and to establish attraction of foreign patients as one of the development directions for 2017. This, along with the development of services helped to increase the number of foreign patients in 2017, and facilitated the inclusion of LJMC in the registry of medical tourism service providers maintained by the Health Inspectorate of Latvia.

LJMC not only successfully attracted foreign patients in 2017, but also actively popularised paid medical services among local public, thus ensuring increase in the number of patients living in Latvia, promoting competitiveness and recognition of LJMC.

In 2018, LJMC signed agreements with the National Health Service for the provision of state paid medical services in the amount provided by the budget for 2018.

On 24 March 2016, a construction contract was singed with SIA Selva būve for the reconstruction of the building owned by LJMC and construction of Radiology Department at 23 Patversmes iela, Riga. The contractual amount is EUR 920 792 excluding VAT. On 2 May 2017 the Construction State Control Office concluded a commissioning certificate regarding Radiology Department at Patversmes iela 23, Riga. After the commissioning Radiology Department became fully operational in 2017 offering all planned services (magnetic resonance, X-ray examinations and ultrasonography), gradually increasing the amount and quality of services (both state paid services and services paid by patients). A cooperation agreement on the availability and payment of PET/CT radiological examinations has been concluded.

Management Report

In 2013, LJMC completed a significant 3-year investment project of EUR 2.3 million, using also EBRD support. The above investment project included a renovation of the old building complex of Latvijas Jūras Medicīnas Centrs and improvement of its territory according to the standards of modern medical facilities and investments were made in new medical equipment establishing Sarkandaugavas Ambulatorās Veselības Aprūpes Centrs (SAVAC). In 2017 SAVAC in its operation has attracted by 20% more new customers than in 2016. The partial re-profiling from inpatient to out-patient services has already increased, and is expected to continue to increase, the effectiveness of operation of LJMC by enabling maximum use of resources available to the centre and providing a higher quality medical care to patients.

Further development of the Company

To attract more foreign and local patients in 2018 LJMC will continue making investments to implement innovative solutions for providing medical services, improve qualification of staff and enhance patient service. LJMC will also continue the state policy in re-profiling of hospitals to ambulatory healthcare institutions.

Continuing to improve the available services with highly-qualified and professional diagnostics service, LJMC's Radiology Department as one of the most modern and innovative cancer diagnostics centre in Eastern Europe will promote the increase in the number of local and foreign patients.

By attracting patients not only from Latvia and other Baltic countries, but also from other EU countries and offering high-quality medical services, LJMC will increase its competitiveness in the Baltics medical market.

Financial results

In the 3 months of 2018, LJMC operated in accordance with the budget approved for 2018. The profit of LJMC is EUR 112 660. LJMC continues to implement an intensive investment policy, which is aimed at increasing the competitiveness and profitability of the Company in the future. The planned amount of investment for 2018 is EUR 200 000.

Risk Management

LJMC continues carrying out activities seeking to limit the negative impact of potential financial risks on the financial position of LJMC by implementing a set of control and analysis measures. Financial assets exposed to credit risk are mostly cash, trade receivables and other receivables. Credit risk is managed by LJMC by performing regular debtor control procedures and debt collection measures aiming to identify and solve any problems on a timely basis.

Liquidity risk is managed by LJMC in line with the principle of prudence ensuring that appropriate credit resources are available to cover liabilities as they fall due. LJMC does not use loans.

Management Report

Subsequent events

On 23 February 2018, LJMC made a public announcement that it has sold its 50.4% shares of SIA Klīnika Dzintari and has received payment of EUR 69 049 in return.

In March 2018 AS Latvijas Jūras medicīnas centrs has provided public information that it has sold its real estate at Vecmīlgrāvja 5. līnijā 26 in the amount of EUR 190 000. No other significant subsequent events have occurred that would materially impact the presentation of the financial statements.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

27 April 2018

Financial statements

Profit and Loss Statement for 3 month of 2018

		Note	31.03.2018 EUR	2017 EUR	31.03.2017 EUR
1.	Net sales from other types of operations	2	1 670 386	5 877 282	1 594 545
2.	Cost of services	3	(1 537 262)	(5 465 933)	(1 435 681)
3.	Gross profit		133 124	411 349	158 864
4.	Administrative expenses	4	(123 009)	(498 739)	(134 343)
5.	Other operating income	5	102 583	233 691	126 662
6.	Other operating expenses	6	(60)	(344 435)	(7 043)
7.	Income from investments in related companies	7	-	636 966	-
8.	Interest and similar income	8	22	54 930	-
9.	Profit before income taxes		112 660	493 762	144 140
10.	Corporate income tax for the reporting year		-	(15 115)	-
11.	Profit after corporate income tax		112 660	478 647	144 140
12.	Income from changes in balances of deferred tax liabilities		-	27 842	-
13.	Profit for the year		112 660	506 489	144 140
	Number of shares Earnings per share (EUR)		800 000 0.14	800 000 0.63	800 000 0.18

* Profit or loss after corporate income tax/ total shareholders' equity

The accompanying notes on pages 13 to 30 form an integral part of these financial statements.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

Chief Accountant Gunta Kaufmane

Balance Sheet as at 31 March 2018

	Note	31.03.2018	31.12.2017	31.03.2017
Assets		EUR	EUR	EUR
Long -term investments				(
I Intangible assets: Concessions, patents, licenses, trademarks and similar rights		2 489	2 923	7 243
Total intangible assets:		2 489	2 923	7 243
II Fixed assets: 1. Land, buildings and engineering structures 2. Equipment and machinery 3. Other fixed assets 4. Construction in progress		4 567 220 111 772 54 950 1332	4 603 395 113 259 60 176 1 332	4 090 309 147 789 58 375 1 031 758
Total fixed assets:	8	4 735 274	4 778 162	5 328 231
III Long term financial investments: 1. Investment in subsidiaries Total long term financial investments: Total long term investments:		4 737 763	- - 4 781 085	- - 5 335 474
Current assets
I Stock:
1. Raw materials 2. Prepayments for stock		101 299	120 393 -	148 357 -
Total stock:	9	101 299	120 393	148 357
II Receivables: 1. Trade receivables 2. Due from related parties 3. Other debtors Due from related parties 4. Prepaid expenses		324 589 52 716 28 318	235 826 40 391 8 935 26 760	237 041 - 123 497 -
Total receivables: Prepaid expenses		92	311 912	360 538
Prepaid expenses III Assets held for sale: IV Cash: 4. Prepaid expenses	11 14	405 715 - 1 748 410	259 660 1 391 298	- 2 039 812
Total current assets:		2 255 424	2 083 263	2 548 707
Total assets		2 255 424 6 993 187	6 864 348	7 884 181

-

The accompanying notes on pages 13 to 30 form an integral part of these financial statements.

Balance Sheet as at 31 March 2018

	Notes to the
	Financial Statemen ts	31.03.2018	31.12.2017	31.03.2017
Equity and Liabilities		EUR	EUR	EUR
Shareholders' equity:
1. Share capital	15	1 120 000	1 120 000	1 120 000
2. Long term investment revaluation reserve	17	2 292 360	2 292 360	2 057 203
3. Reserves:
b) reserves provided by the Company's Statutes		63 819	63 819	63 819
4. Retained earnings	16
a) retained earnings carried forward from previous years		2 454 235	1 835 086	2 917 783
b) profit of the reporting year		-	506 489
c) non-controlling interest				133 031
Total shareholders' equity:		5 930 414	5 817 754	6 291 836
Liabilities:
Long term liabilities:
1. Next period income	20	411 669	411 669	421 247
2. Deferred tax liabilities	7	-	-	390 878
Total long term liabilities:		411 669	411 669	812 125
Short term liabilities:
1. Customer advances		1 755	1 755	-
2. Accounts payable to suppliers and contractors		124 572	131 714	752 294
3 Taxes and compulsory state social security
contributions	19	141 827	146 686	-
4. Other liabilities	18	187 091	158 911	-
5. Next period income	20	18 752	18 752	-
6. Accrued liabilities	21	177 107	177 107	27 926
Total short term liabilities:		651 104	634 925	780 220
Total liabilities:		1 062 773	1 046 594	1 592 345
Total equity and liabilities		6 993 187	6 864 348	7 884 181

The accompanying notes on pages 13 to 30 form an integral part of these financial statements.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

Chief Accountant Gunta Kaufmane

	Statement of Changes to the Shareholders Equity for 3 month of 2018
--	---------------------------------------------------------------------

	Share capital	Long term investment revaluation reserve	Reserves	Retained earnings brought forward from previous	Profit/loss of the reporting year	Total equity
	EUR	EUR	EUR	years EUR	EUR	EUR
Balance as at 31 December 2016 Profit of 2016	1 120 000	2 057 203	63 819	1 913 216	241 870	5 396 108
transferred to retained earnings of previous years	-	-	-	241 870	(241 870)	-
Reversal of deferred	-	363 036	-	-	-	363 036
tax (see Note 9) Dividends for 2016 Profit for the year	- -	- -	- -	(320 000) -	- 506 489	(320 000) 506 489
Balance as at 31 December 2017	1 120 000	2 292 360	63 819	1 835 086	506 489	5 817 754
Profit of 2016 transferred to retained earnings of previous years	-	-	-	-	-	-
Dividends for 2017 Profit for the year	- -	- -	- -	- -	-	- -
Balance as at 31 December 2017	1 120 000	2 292 360	63 819	1 835 086	506 489	5 817 754
Profit of 2017 transferred to retained earnings of previous years Disposal of disposed fixed asset reserve				506 489	(506 489)	-
Dividends for 2017 Profit for the year					112 260	112 260
Balance as at 31	1 120 000	2 292 360	63 819	2 341 575	112 260	5 930 414
March 2018

The accompanying notes on pages 13 to 30 form an integral part of these financial statements.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

Chief Accountant Gunta Kaufmane

Statement of Cash Flows for 3 month of 2018

	Note	31.03.2018 EUR	2017 EUR	31.03.2017 EUR
I. Cash flows from operating activities
1. Profit before corporate income tax Adjustments for:		112 660	493 762	144 140
a) depreciation and amortisation		56 850	271 379	67 442
b) negative revaluation of fixed assets, net c) loss from disposal of fixed assets	6, 8		330 396 (6 953)	5 855 -
d) income from investments in related companies			(636 966)	-
2. Profit before adjustments for the effect of changes to current assets and short term liabilities;		169 510	449 618	217 437
Adjustments for: a) decrease/(increase) in trade receivables b) decrease/(increase) in stock		(93 803) 19 094	27 021 11 069	(12 309) (14 223)
c) increase in the accounts payable to suppliers and other liabilities		16 179	25 911	(100 490)
3. Gross cash flows from operating activities 4. Corporate income tax		110 980 -	513 619 (35 207)	90 415 -
5. Net cash flows from operating activities II. Cash flows from investing activities		110 980	478 412	90 415
a) dividends received	8	69 660	636 966	(626 824)
b) purchase of fixed and intangible assets	8	(13 528)	(605 510)	(296 298)
c) profit from the decrease of subsidiary's equity		-	85 641	-
d) profit from disposal of fixed and intangible assets		190 000	12 810	-
6. Net cash flows used in investing activities III. Cash flows from financing activities		246 132	129 907	(923 122)
a) dividends paid		-	(320 000)	-
7. Net cash flows used in financing activities		-	(320 000)	-
Net increase/(decrease) in cash and cash
equivalents in the reporting year		357 112	288 319	(832 707)
Cash and cash equivalents at the beginning of the year		1 391 298	1 102 979	2 872 519
Cash and cash equivalents at the end of the year	14	1 748 410	1 391 298	2 039 812

The accompanying notes on pages 13 to 30 form an integral part of these financial statements.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

Chief Accountant Gunta Kaufmane

(1) Information on the Company's activities and summary of significant accounting principles

Information on the Company

The legal address of A/s Latvijas Jūras medicīnas centrs is 22 Patversmes iela, Riga. The Company was registered with the Commercial Register under the common registration number 40003306807. The largest shareholders of the Company are Ilze Birka (17.50%), Mārtiņš Birks (17.50%), Jānis Birks (12.80%), Guna Švarcberga (10.36%), Ilze Aizsilniece (8.82%), Adomas Navickas (6.85%).

The Board comprises Jānis Birks (Chairperson of the Board), Juris Imaks (Board Member) and Anatolijs Ahmetovs (Board Member). The Chairperson of the Council is Mārtiņš Birks, Council Members are Viesturs Šiliņš, Ineta Gadzjus, Jevgēņija Kalējs and Uldis Osis.

The core business of the Company according to NACE rev 2. is Hospital activities (NACE 86.10); Retail sale of medical and orthopaedic goods in specialised stores (47.74); Education n.e.c. (85.59); General medical practice activities (86.21); Special medical practice activities (86.22); Dental practice activities (86.23); Other human health activities (86.90); Residential nursing care activities (87.10); Other residential care activities (87.90); Other social work activities without accommodation n.e.c. (88.99); Physical well-being activities (96.04); Other personal service activities n.e.c. (96.09).

Basis of preparation

The financial statements were prepared in accordance with the law 'On Accounting' and the 'Annual Reports and Consolidated Annual Report Law' of the Republic of Latvia. Until July 2017 the Company's management used the exemption under Section 13 of the Annual Reports and Consolidated Annual Reports Law and in these financial statements – available on www.nasdaqbaltic.com – it continued to recognise, measure and disclose deferred tax liabilities according to the International Accounting Standards (International Financial Reporting Standards as adopted by the EU) and provided appropriate disclosures on these items. See Note 9 and 20, as well as Section 'Corporate income tax' of Note 1 regarding the impact of changes in tax legislation to deferred tax as at 31 December 2017.

In addition, the Company's management used the exemption under Section 13 of the Annual Reports and Consolidated Annual Reports Law and in these financial statements it recognises and measures Assets held for sale according to the International Accounting Standards and provided appropriate disclosures on these items in Note 11.

According to Article 3(6) of the Annual Reports and Consolidated Annual Reports Law, the Company applies the requirements of the law applicable to large companies as its transferable securities are included in the regulated market of the Republic of Latvia.

The profit and loss statement was prepared according to the turnover costing method. The cash flow statement was prepared according to the indirect method. The financial statements are prepared on the historical cost basis except for the fixed assets disclosed under 'Land, buildings and engineering structures' and 'Assets held for sale' – land and buildings, which are measured using a revaluation method.

Accounting principles

The financial statements were prepared in accordance with the following policies:

• a) Going concern assumption that the Company will continue as a going concern;
• b) Consistent valuation principles with those used in the prior year;
• c) Items were valued in accordance with the principle of prudence, i.e.:
  • the financial statements reflect only the profit generated to the balance sheet date;
  • all incurred liabilities and current or prior year losses have been taken into consideration even if discovered within the period after the date of the balance sheet and preparation of the financial statements; and,
  • all amounts of impairment and depreciation have been taken into consideration irrespective of whether the financial result was a loss or profit.

Address: Patversmes iela 23, Riga, LV-1005 Unified registration number: 40003306807

Notes to the Financial Statements

• d) Income and expenses incurred during the reporting year have been taken into consideration irrespective of the payment date or date when the invoice was issued or received; Expenses were matched with revenue for the reporting period.
• e) Assets and liabilities have been valued separately.
• f) The opening balance agrees with the prior year closing balance;
• h) Business transactions are recorded taking into account their economic contents and substance, not the legal form.

Related parties

Related parties represent both legal entities and private individuals related to the company in accordance with the following rules.

a) A person or a close member of that person's family is related to a reporting entity if that person:

• i. has control or joint control over the reporting entity;
• ii. has significant influence over the reporting entity; or
• iii. is a member of the key management personnel of the reporting entity or of a parent of the reporting entity.
• b) An entity is related to a reporting entity if any of the following conditions applies:
  • i. The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others);
  • ii. One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member);
  • iii. Both entities are joint ventures of the same third party;
  • iv. One entity is a joint venture of a third entity and the other entity is an associate of the third entity;
  • v. The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity.
  • vi. The entity is controlled, or jointly controlled by a person identified in (a);
  • vii. a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
  • viii. The entity or any member of the group to which the entity belongs provides management personnel services to the entity or the parent of company of the entity.

Related party transaction – A transfer of resources, services or obligations between a reporting entity and a related party, regardless of whether a price is charged.

Financial instruments and financial risks

Financial instrument is an agreement that simultaneously results in financial assets of one party and financial liabilities of the other party.

The key financial instruments held by the Company are financial assets such as trade receivables, amounts due from related parties and other receivables, and financial liabilities such as prepayments from clients, accounts payable to suppliers and contractors and other creditors arising directly from its business activities.

Financial risks connected with the Company's financial instruments, financial risk management Key financial risks related to the Company's financial instruments are:

• Credit risk is the risk that the Company may incur financial losses if parties to the transactions fail to fulfil their liabilities under the contracts, and credit risk is primarily connected with trade receivables;
• Currency risk– risk that the Company may suffer unexpected losses arising from fluctuations in the foreign exchange rates; the Company is not exposed to currency risk as it does not significant amounts of currencies other than EUR.
• Interest rate risk risk that the Company may incur losses due to fluctuations in interest rates;
• Liquidity risk risk that the Company will not be able to meet its financial liabilities in due time.

Management has implemented procedures to control the key risks.

Credit risk

The inability of insurance companies and patients to pay for the services provided by the Company in due time and in full amount. Most of the services are paid for within a short period of time after the provision of services or are funded by state or insurance providers, so the credit risk is low.

Interest rate risk

Management believes that interest rate risk is not material.

Liquidity risk

The Company has no external loans and it has significant financial resources to settle its liabilities.

Fair value of financial assets and liabilities

Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction. Financial assets and financial liabilities are carried at cost which according to management approximates their fair value at acquisition plus any related additional expenses. Purchase costs are acquisition costs of goods or services (net of discounts received) with added additional costs related to the purchase.

Reporting period

The reporting period is the 3 months from 1 January 2018 to 31 March 2018.

Currency unit and revaluation of foreign currency

All amounts in these financial statements are expressed in the official currency of Latvia – euro (EUR), the functional currency of the Company.

Foreign currency transactions are translated into EUR according to currency exchange rates effective at the date of transaction and determined by reconciliation of the system of the European Central Bank and other central banks and which is published on the website of the European Central Bank.

As at the reporting date, all monetary assets and liabilities are translated into EUR according to exchange rates published on the website of the European Central bank. Non-monetary items of assets and liabilities are revalued to euros in accordance with the reference exchange rate published by the European Central Bank on the transaction date.

Exchange rate per EUR 1:

	31.12.2017	31.12.2016
USD	1.19930	1.0541

Gain or loss resulting from payments under transactions executed in foreign currencies and the translation of monetary assets and liabilities denominated in foreign currencies is reflected in the profit and loss statement of the respective period.

Estimates and judgements

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. The actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Changes in the accounting estimates are recognised in the period when those estimates are reviewed and in the future periods.

Key sources of estimation uncertainty are the following:

(i) Impairment of fixed assets

An impairment loss is recognised whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable value. The recoverable amount is the highest of the fair value less selling expenses or value in use. Impairment losses are recognised in the profit and loss statement.

(ii) Useful lives of fixed and intangible assets

Management estimates the useful lives of fixed and intangible assets in proportion to the expected duration of use of the asset (its expected capacity or effectiveness) based on historical experience with similar fixed assets and future plans. Land is not subject to depreciation. For other assets, depreciation and amortization is calculated on a straight-line basis over the entire useful life of the respective intangible asset and fixed asset in order to write their value or revalued value down to the estimated book value at the end of the useful life based on the following rates:

	%
Intangible assets	20
Buildings and constructions	2.5 - 2.85
Communication equipment and instruments	33.33
Other fixed assets	20

Current maintenance and repair costs of fixed assets are recognized in the profit and loss statement as incurred.

(iii) Fixed assets

Fixed assets other than land, buildings and constructions are carried at cost less accumulated depreciation and impairment losses.

Land, buildings and constructions are measured by the Company using the revaluation model. The balance sheet item Land, buildings and engineering structures of the financial statements of the Company is presented at revalued value, which equals fair value at the revaluation date net of subsequent accumulated deprecation and impairment loss.

Based on the Company's position as at 31 December, the Company has estimated the value of the balance sheet item 'Land, buildings and engineering structures', and in accordance with the estimation, determined the carrying amount of all land, buildings and engineering structures in line with market value and based on valuation of external certified valuers.

According to the policy, revaluation of a single building or construction requires the whole category to be revalued. To determine the impact of revaluation at the date of revaluation accumulated depreciation is eliminated against the cost or other value, which replaces cost in the financial statements, and the gross carrying amount is increased or decreased according to the revalued value of the building or structure in the following manner: accumulated depreciation to the date of revaluation is written-off against the current carrying amount of fixed asset, and afterwards the residual value is increased or decreased according to the fair value of fixed asset as a result of revaluation.

In case the fair value of fixed assets at the balance sheet date is lower than their carrying amount, and such impairment is expected to be permanent, fixed assets are recognized at the lower value. The revaluation result is recognized in the profit and loss statement except where a previously recognized increase in the value of fixed assets offsets an impairment loss. In that event, the long term investment revaluation reserve is decreased by the amount of impairment.

In case the value of fixed assets at the balance sheet date is higher than the valuation on the balance sheet, fixed assets are revalued to the higher value if the increase in value may be assumed to be other than temporary. The increase in value resulting from revaluation is recognized under 'Long term investment revaluation reserve'. If an increase in the value resulting from revaluation compensates for the impairment of the same fixed asset which was previously recognized as an expense in the profit and loss statement, then the increase resulting from revaluation is recognized as income in the profit and loss statement as incurred. The long term investment revaluation reserve is decreased when the revalued asset is disposed, is no longer utilized, or the increase of value is no longer reasonable.

The increase in value recognized in the long term investment revaluation reserve under equity is reversed by recognizing a decrease in the profit and loss statement upon liquidation or disposal of the revalued fixed asset.

(iv) Valuation of receivables

Receivables are disclosed at amortised cost net of impairment allowances. Doubtful debt allowances are recognized based on an individual management assessment of the recoverability of each receivable when objective evidence exists that the Company will not be able to recover the full amount of receivables according to the previously agreed repayment terms. The amount of allowance represents the difference between the carrying and recoverable amount of receivables. The allowance is charged to the profit and loss statement.

(v) Provisions

Provisions are recognized when a past event has given rise to a present obligation or losses and the amount can be estimated reasonably. The likelihood of loss is assessed based on management assumptions. In order to determine the amount of loss management is required to select an appropriate calculation method and make specific assumptions connected with the specific risk.

Revenue recognition

Income from sales of goods

Revenue from the sales of goods is recognized in the profit and loss statement after the risks and rewards of ownership are transferred to the client.

No revenue is recognized if according to the provisions of the transaction the Company retains significant risks pertaining to the ownership of goods and the goods can be returned.

Income from services

Income from services provided is recognized in the profit and loss statement as generated. Income is received and recorded according to signed cooperation agreements.

Rental income

Rental income is recognised on a straight-line basis over the rental term.

Dividend income

Dividends are recognized when the Company incurs a legal right to receive them.

Long and short term classification

Amounts whose terms of receipt, payment or write off are due more than one year after the balance sheet date are classified as long term. Amounts to be received, paid or written off within 12 months are classified as short-term.

Lease transactions

Operating lease – (the Company as a Lessor)

The Company leases premises, which are part of revalued fixed assets. Depreciation is calculated on a straight-line basis over the entire useful life of the respective tangible asset in order to write their value down to the estimated book value at the end of the useful life based on the rates set for similar tangible assets. Income from operating lease and client prepayments is charged to the profit and loss statement on a straight-line basis over the period of lease.

Operating lease – (the Company as a lessee)

Payments for operating lease are recognized in the profit and loss statement on a straight line basis over the period of lease.

Fixed assets

All fixed assets other than land, buildings and constructions are recognised on the balance sheet at historical cost less depreciation.

For other assets, depreciation and amortization is calculated in accordance with the straight-line method over the entire useful life of the respective intangible assets and fixed assets in order to write their value or revalued value down to the estimated book value at the end of the useful life.

The depreciation method is reviewed at least on an annual basis, at the year-end.

Subsequent expenses are added to the book value of the asset or recognized as a separate asset only where it is highly probable that future benefits related to this item would flow into the company and expenses of this item can be estimated reliably. Such expenses are written off over the entire useful life of the respective asset. When capitalizing the costs of installed spare parts, the book value of the spare parts is written off in the profit and loss statement.

Profit or loss from disposal of fixed assets is calculated as the difference between the carrying amount of the asset and income generated from sale, and income from the reversal of the revaluation reserve of the respective fixed asset, and charged to the profit and loss statement as incurred.

Accounting and valuation of stock

Stock is carried at the lower of cost and net realizable value. Stock has been valued according to the FIFO method. Stock accounting is based on the perpetual method. Stock has been counted during the annual stock take.

Assets held for sale

Assets held for sale are such objects for which the balance sheet value will be recovered in a trading transaction rather than in the course of further utilization, and that comply with both of the classification criteria:

• these objects in their current condition are available for immediate sale and are subject only to common selling conditions of such objects;
• their trading transaction is credible.

Assets held for sale are not subject to amortisation.

Assets held for sale that prior to reclassification were carried at cost are recognised according to the carrying amount at the date of reclassification. Assets held for sale that prior to reclassification were measured using revaluation method cost are recognised at fair value.

Assets held for sale are recognized at the lowest of carrying amount, comparing the carrying amount and net realisable value of those assets.

Grants

Grants received for special types of capital investments are treated as deferred income which is gradually recognised as revenue over the useful life of the fixed assets received or acquired using grants. Grants received to cover expenses are recognised in the same period when the related expenses have arisen, if all the conditions of receiving the grant are met.

Corporate income tax

(a) Current tax

In the reporting year

Current tax for the reporting year is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially enacted at the reporting date, and any adjustment to tax payable in respect of previous years. See below for information on changes effective as of 1 January 2018.

Changes to the calculation of Corporate Income Tax as of 1 January 2018

As of 1 January 2018, the new Law on Enterprise Income Tax of the Republic of Latvia comes into effect setting out a new regime for paying taxes. As of the date, the tax rate will be 20% instead of the current 15%, the taxation period will be one month instead of a year and the taxable base will include:

• distributed profit (dividends calculated, payments equalled to dividends, conditional dividends) and
• conditionally or theoretically distributed profit (non-operating expenses, doubtful debts, excessive interest payments, loans to related parties, decrease of income or excessive expenses which are incurred by entering transactions at prices other than those on the market that should be calculated using the methodology determined by the Cabinet of Ministers, benefits bestowed by the non-resident upon its staff or board (council members) regardless of whether the receiving party is a resident or a non-resident, if they relate to the operation of a permanent establishment in Latvia, liquidation quota).

(B) Deferred tax

In accordance with the Annual Reports and Consolidated Annual Reports Law of the Republic of Latvia, companies are permitted to recognise deferred tax supported by justified reasons. In such cases, deferred tax should be recognised, assessed and disclosed in the financial statements in line with the International Financial Reporting Standards as adopted by the EU. Under IAS 12 Income taxes, whenever there is a difference to tax rates being applied to distributed and undistributed profits deferred tax assets and liabilities should be recognised by applying the rate applicable to undistributed profits.

According to the new Law on Enterprise Income Tax of the Republic of Latvia adopted on 28 July 2017, and effective as of 1 January 2018, a 20% rate is only applied to distributed profit, while a 0% rate is expected to be applied to undistributed profits. Therefore, deferred tax assets and liabilities are recognisable at nil amount. This principle has been applied in the Company's financial statements for the year ended 31 December 2017.

Deferred tax assets and liabilities were reversed and changes were charged to profit or loss in the reporting period, except when deferred tax was recognised in relation to revaluation reserves. In that case, reversal of deferred tax was charged to revaluation reserves as disclosed in Note 9.

(2) Net sales

Net sales represents revenue generated during the reporting period from the Company's basic activities – sales of services, net of value added tax and discounts.

	2018 EUR	2017 EUR
Ambulatory medical services	1 537 277	5 347 200
Services covered by insurance	129 430	507 431
Paid ambulatory medical services	72 480	282 131
Paid in-patient care	56 950	225 300
In-patient care		-
Dental services	3679	17 395
Resident training	-	5 256
	1 670 386	5 877 282

The Company provides services only in the territory of the Republic of Latvia.

The Company does not disclose information on distribution of net sales by lines of business in accordance with Regulation No. 1893/2006 (EK) of the European Parliament and European Council of 20 December 2006, with which the statistic classification of business activity NACE rev 2 is established, as its disclosure could have a severe negative impact on the interests of the Company.

(3) Cost of services

The item represents costs incurred for generating net sales – such as costs of goods and services at acquisition cost, and costs related to purchase of goods and services.

	2018	2017
	EUR	EUR
Remuneration	689 627	2 479 681
Medicines, medical materials	200 590	721 768
Compulsory state social security contributions	162 853	571 812
Non-deductible value added tax	81 939	313 778
Lease of equipment	110 446	289 104
Depreciation	56 850	271 379
Utilities and maintenance	77 186	241 120
Office items and equipment, other materials	45 896	170 485
Repair costs	39 036	128 494
Medical examinations and other services	18 148	49 064
IT expenses	7 933	26 861
Advertisement expenses	3 888	24 273
Security	4 335	24 368
Changes in doubtful debt allowances	-	21 578
Medical fund risk expenses	-	14 160
Transport	1718	11 181
Office expenses	2670	11 787
Patient catering expenses	1821	10 684
Real estate tax	-	7 845
Insurance	701	4 388
Staff training	223	4 509
Risk duty	373	1 361
Benefits and gifts to employees	702	1 207
Changes in cost of accrued vacations	-	-
Other costs related to services	30 327	65 046
	1 537 262	5 465 933

(4) Administrative expenses

	2018	2017
	EUR	EUR
Remuneration	83 300	318 077
Compulsory state social security contributions	19 610	72 936
Communication expenses	4 798	60 770
Audit of the financial statements	3 089	13 750
Office expenses	2 905	10 372
Bank services	2 257	7 833
Legal activities	6 558	5 646
Representation expenses	336	2 141
Other	156	7 214
	123 009	498 739

(5) Other operating income
	2018	2017
	EUR	EUR
Income from rent	78 105	122 680
Amortisation of funds received from EBRD	-	18 752
Recovered overpaid taxes	-	-
Other income	24 478	92 259
	102 583	233 691

Other income consists of income from catering and laundry service, advertising and beauty care services.

(6) Other operating expenses

	2018 EUR	2017 EUR
Loss from revaluation of long-term assets (see Note 10)	-	333 390
Loss on disposal of fixed assets, net	-	5 857
Penalties	-	2 802
Other expenses	60	2 386
	60	344 435

Address: Patversmes iela 23, Riga, LV-1005 Unified registration number: 40003306807

Notes to the Financial Statements

(7) Corporate income tax

(i) Corporate income tax recognised in the profit and loss statement

	2018	2017
	EUR	EUR
Current tax	-	15 115
Deferred tax		(27 842)
	-	(12 727)

(ii) Reconciliation of effective income tax rate

Income tax expenses disclosed for the years ended 31 December 2017 and 2016 are different from the amounts calculated by applying the statutory rate to the Company's profit before taxes as reflected below:

	2018	2017
	EUR	EUR
Profit/(loss) before corporate income tax		493 762
Theoretically calculated corporate income tax, 15%		74 064
Effect of non-deductible expenses		54 457
Effect of non-taxable income		(113 406)
Reversal of deferred tax		(27 842)
Corporate income tax for the reporting year	-	(12 727)

(iii) Deferred tax

Deferred tax relates to the following temporary differences:

		2018 EUR	2017 EUR
Depreciation	assets	liabilities - -	assets -	liabilities -
Net deferred tax liabilities		- -	-	-

Total movements in deferred tax:

	2018	2017
	EUR	EUR
Deferred tax liabilities, beginning of the period		390 878
Changes in deferred tax recognized in the profit or loss statement		(27 842)
Recognised deferred tax changes from revaluation		-
Adjustment to deferred tax recognized in the revaluation reserve		(363 036)
Deferred tax liabilities, end of the period		-

(8) Intangible assets and fixed assets

	Intangi ble assets	Land, buildings and engineerin g	Equipment and machinery	Other fixed assets	Construction in progress	Total
	EUR	structures EUR	EUR	EUR	EUR	EUR
Historical cost
31.12.2016	81 960	4 683 297	3 495 743	474 574	864 159	9 599 733
Additions	-	-	42 424	35 462	527 624	605 510
Reclassification*	-	1 382 824	-	7 627	(1 390 451)	-
Accumulated depreciation allocated to historical cost before revaluation	-	(616 518)	-	-	-	(616 518)
Negative result of revaluation allocated to the profit and loss statement	-	(333 390)	-	-	-	(333 390)
Negative result of revaluation allocated to reserves Positive result of	-	(218 354)	-	-	-	(218 354)
revaluation allocated to reserves	-	125 402	-	-	-	125 402
Reclassified to assets held for sale	-	(190 000)	-	-	-	(190 000)
Disposals	(1 412)	(151 622)	(745 100)	(17 702)	-	(915 836)
31.12.2017	80 548	4 681 639	2 793 067	499 961	1 332	8 056 547
Additions Reclassification*	-	-	12 892	636	-	13 528
Disposals		(33 293)	(16 150)	(579)		(50 022)
31.03.2018	80 548	4 681 539	2 789 809	500 018	1332	8 020 053
Accumulated depreciation
31.12.2016	73 677	671 874	3 327 276	425 820	-	4 498 647
Depreciation for 2017	5 360	142 577	91 777	31 665		271 379
Depreciation of disposed fixed assets Accumulated	(1 412)	(119 689)	(739 245)	(17 700)	-	(878 046)
depreciation allocated to historical cost before revaluation	-	(616 518)	-	-	-	(616 518)
31.12.2017	77 625	78 244	2 679 808	439 785	-	3 275 462
Depreciation for 2018 Depreciation of disposed fixed assets	434	36 175	14 379	5862	-	56 850

Accumulated depreciation allocated to historical cost before revaluation
		(33 293)	(16 150)	(579)		(50 022)
31.03.2018	78059	81126	2 678037	445068	-	3 282 290
Balance as at 31.12.2017	2 923	4 603 395	113 259	60 176	1 332	4 781 085
Balance as at 31.03.2018	2489	4 567 220	111 772	54 950	1332	4 737 763

* Transferred from construction in progress at Radiology Department, Patversmes 23 (EUR 1 382 824).

In February 2018, during the preparation of these financial statements land, buildings and constructions were valued by independent experts. The valuation was carried out by the independent experts using a combination of the comparable transactions method and income method. According to the management, the fair value of these assets approximates their carrying amount after revaluation as at 31 December 2017. The result of a upward revaluation of buildings and constructions at Melīdas iela 10 by EUR 95 402 was recognised as an increase in long-term investment revaluation reserve. The result of a upward revaluation of land at Patversmes iela 23 by EUR 30 000 was recognised as an increase in long-term investment revaluation reserve.

The result of revaluation of buildings and constructions at Patversmes iela 23 by EUR 336 931 was recognised as a decrease in previously recognised long-term investment revaluation reserve.

The result of a downward revaluation of buildings and constructions at Vecmīlgrāvja 5. līnija by EUR 214 813 was recognised as a decrease in previously recognised long-term investment revaluation reserve.

Information on changes due to revaluation

	2018 EUR	2017 EUR
Appreciation due to revaluation Impairment due to revaluation		125 402 (551 744)
Net changes in the value of fixed assets due to revaluation, including:		(426 342)
Increase from revaluation allocated to the decrease in the long term investment revaluation reserve		125 402
Gross decrease from revaluation allocated to the decrease in the long term investment revaluation reserve		(218 354)
Decrease from revaluation allocated to the profit and loss statement		(333 390)
		(426 342)

The fair value of land and building was determined by an external, independent property valuer, having appropriate recognised professional qualification and recent experience in the location and category of the property being valued.

The following table shows the valuation technique used in measuring the fair value of core real estate items included in position 'Land, buildings and engineering structures', as well as the significant unobservable inputs used:

			Inter-relation between
		Significant	significant unobservable inputs
Type	Valuation method	unobservable data	and fair value measurement

Address: Patversmes iela 23, Riga, LV-1005 Unified registration number: 40003306807

Notes to the Financial Statements

Buildings and land in the amount of EUR 3 100 000 at Patversmes iela, Riga	Fair value has been estimated based on the average of: Market comparison technique: The fair value was based on results of comparable sales of similar buildings. Discounted cash flow technique: The model is based on discounted cash flows from rendering services	Price per m2 EUR 470 Rent rate per m2 – EUR 2.3-9 Capacity – 90% Capitalisation rate – 9%	The fair value would increase (decrease) if the price per m2 was higher (lower). The estimated fair value would increase (decrease), if: Rent rate would be higher (lower); Capacity percentage would be higher (lower); Capitalisation rate would be lower (higher);
Buildings and land in the amount of EUR 850 000 at Vecmīlgrāvja 5.līnija, Riga	Fair value has been estimated based on the average of: Comparison approach: The fair value was based on results of comparable sales of similar buildings. Discounted cash flow method;: The model is based on discounted cash flows from rendering services	Price per m2 EUR 349 Rent rate per m2 – EUR 3.5-5 Capacity – 90% Capitalisation rate – 10%	The fair value would increase (decrease) if the price per m2 was higher (lower). The estimated fair value would increase (decrease), if: Rent rate would be higher (lower); Capacity percentage would be higher (lower); Capitalisation rate would be lower (higher).
Type	Valuation method	Significant unobservable data	Inter-relation between significant unobservable inputs and fair value measurement
Buildings and land in the amount of EUR 640 000 at	Fair value has been estimated based on the average of:		Fair value would increase (reduce) if the price per m2 was higher (lower)
Melīdas iela, Riga	Comparison approach: The fair value was based on results of comparable sales of similar buildings.	Price per m2 EUR 334	The estimated fair value would increase (decrease), if: Rent rate would be higher (lower);

Discounted cash flow method;: The model is based on discounted cash flows from rendering services	Rent rate per m2 EUR 1-4.7 Capacity – 90%	Capacity percentage would be higher (lower); Capitalisation rate would be lower (higher).
	Capitalisation rate – 9.0%

In 2017, the management initiated sales process for a real estate at Vecmīlgrāvja 5. līnijā 26. This real estate property was reclassified to Assets held for sale at fair value. In March 2018 the object was sold. Refer to Note 11.

According to Section 52(2)(2) of the Annual Reports and Consolidated Annual Reports Law, disclosures are provided concerning revalued fixed assets indicating their value had revaluation not taken place:

The carrying amount of 'Land, buildings and engineering structures' as at 31.12.2017 had revaluation not taken place would be EUR 3 071 601 (31.12.2016 – EUR 1 784 151). Including: 2018 31.12.2017

EUR
4 021 290
(949 689)
EUR

(9) Stock

	2018 EUR	31.12.2017 EUR
Medicines in warehouse, pharmacy	90 347	103 994
Medicines in departments	8 963	8 588
Other materials	1 989	7 811
	101 299	120 393
(10) Trade receivables	2018 EUR	31.12.2017 EUR
National Health Service	235 805	157 746
Insurance companies	70 447	50 238
Doubtful debt allowance	(11 757)	(11 757)
Other institutions, companies and individuals	30094	39 599
	324 589	235 826

(11) Due from related parties

	2018 EUR	31.12.2017 EUR
Due from related parties, gross value	70 026	57 701
Doubtful debt allowance	(17 310)	(17 310)
	52 716	40 391

The item presents the amount due from related party Kodolmedicīnas klīnika SIA for rent payments.

(12) Other debtors

	2018 EUR	31.12.2017 EUR
Overpaid taxes (see Note 22)	8 485	2 496
Value added tax on unpaid services	870	4 979
Security deposit		-
Other receivables	18 963	1 460
	28 318	8 935

(13) Prepaid expenses

	2018 EUR	31.12.2017 EUR
Insurance Advertising Press subscription		3 472 297 -
Rent		22 952
Other	92	39
	92	26 760

(14) Cash

By currency:		2018		2017
		Currency	EUR	Currency	EUR
Current account	USD	5 840	4 870	5 840	4 870
Current account	EUR		1 725 890	-	1 381 862
Cash on hand	EUR		4 566	-	4 566
			1 748 410		1 391 298

(15) Share capital

Share capital of the Company as at 31 March 2018 is EUR 1 120 000 and it is divided into 800 000 shares with the nominal value of EUR 1.40.

The share capital of the Company is owned by the following shareholders:

	31.03.2018		31.12.2017
	Number of	Holding (%)	Number of	Holding (%)
	shares		shares
Ilze Birka	140 000	17.50%	140 000	17.50%
Mārtiņš Birks	140 000	17.50%	140 000	17.50%
Ilze Aizsilniece	70 565	8.82%	70 565	8.82%
Guna Švarcberga	82 917	10.36%	82 917	10.36%
Jānis Birks	102 388	12.80%	102 388	12.80%
Adomas Navickas	54 811	6.85%	54 811	6.85%
Other shareholders (up to
5% shares per each)	209 319	26.17%	209 319	26.17%
Total	800 000	100.00%	800 000	100.00%
Share capital (EUR)	1 120 000		1 120 000

All shares of the Company are name (publicly issued shares) shares.

(16) Retained earnings

Retained earnings, including the profit of 2018 of EUR 112 660, as at 31 December 2017 amount to EUR 2 341 575 (2016: EUR 2 155 086).

(17) Revaluation reserves

Revaluation reserve as at 31 December 2017 includes the amount of revaluation of fixed assets. The negative result of revaluation of fixed assets amounting to EUR 92 952 was recognised under 'Revaluation reserve' in equity.

Long term investment revaluation reserve
	2017	2017
	EUR	EUR
Revaluation reserves as at 1 January	2 292 360	2 057 203
Decrease as a result of revaluation	-	(92 952)
Disposal of disposed fixed asset reserve	-	(34 927)
Deferred tax changes from revaluation	-	-
Reversal of deferred tax	-	363 036
Adjustment in deferred tax	-	-
Revaluation reserves as at 31 December	2 292 360	2 292 360
(18) Other liabilities
	2018	31.12.2017
	EUR	EUR
Salaries		158 337
Payments to the trade union		574
Deposited remuneration for work and injunctions		-

158 911

(19) Taxes and compulsory state social security contributions

	Balance as at 31.12.2017	Calculated for 2017	Paid in 2017	Balance as at 31.03.2018
	EUR	EUR	EUR	EUR
Corporate income tax	(2490)	0	(4401)	(6891)
VAT	17 738	24 018	(43344)	(1588)
Real estate tax			-
	(6)	-		(6)
Natural resources tax	1 610	0	(271)	1 339
Risk duty	115	398	(387)	126
Social contributions	82 597	265 533	(253 448)	94 682
Personal income tax	44 626	129 676	(128 622)	45 680
Total	144 190	419 625	(430 473)	133 342
Including:
Overpaid taxes	(2496)			(84 85)
Tax liabilities	146 686			141 827
Overpaid taxes are disclosed under "other receivables".
(20) Next period income
			2018	31.12.2017
			EUR	EUR
The part of capital grants to be charged to profit or loss
within 1 to 5 years			411 669	411 669
Deferred income, long term			411 669	411 669
The part of capital grants to be charged to profit or loss
within one year			18 752	18 752
Deferred income, short term			18 752	18 752

In 2012, the Company received EBRD funding to purchase fixed assets. In 2017, the Company recognised revenue of EUR 18 752 (2016: EUR 27 926) (see Note 5).

(21) Accrued liabilities

	2018 EUR	31.12.2017 EUR
Accrued expenses on unused vacations	177 107	177 107
	177 107	177 107

As at the year-end, the following provisions for employee salaries have been recognized, which are calculated for 2017 and will be paid in 2018 in accordance to the order of calculation of remuneration approved by the management of the Company.

(22) Average number of employees by category

2018	2017
	343
	3
	5
335	335
2018	2017
EUR	EUR
	2 797 758
220 200	644 748
993 127	3 442 506
	2017 EUR
	78 158
4 900	18 436
	27 319
	6 011
	212 600
13 165	48 489
	391 013
	343 3 5 772 927 2018 EUR 20 344 6 829 1 545 56 127 102 910

(25) Future liabilities

As at 31 March 2018, the Company has not incurred future payment liabilities under effective agreements.

The management of the Company has no information on issued guarantees, legal proceedings and other contingent liabilities, which could impact the financial position of the Company as at 31 March 2018.

(26) Related party transactions

In 2018, the Company made transactions with related parties:

— issue invoices to SIA Kodolmedicīnas klīnika for rent payments of EUR 57 701 (2016: EUR 23 447).

(27) Remuneration to the certified auditor

	2018 EUR	2017 EUR
Audit of the financial statements	3 089	13 750
	3 089	13 750

(28) Information on operating lease and rent agreements with a significant impact on the Company's activities

The Company has 25 effective operating lease agreements regarding equipment. According to this agreement, lease payments are the following:

In 2018	EUR 337 920
In 2019-2021	EUR 979 121

(29) Subsequent events

In February 2018 LJMC sold its 50.4% shares in SIA Klīnika Dzintari in the amount of EUR 69 049. In March 2018 AS Latvijas Jūras medicīnas centrs has provided public information that it has sold its real estate at Vecmīlgrāvja 5. līnijā 26 in the amount of EUR 190 000. No other significant subsequent events have occurred that would materially impact the presentation of the financial statements.

Chairperson of the Board Jānis Birks

Member of the Board Juris Imaks

Member of the Board Anatolijs Ahmetovs

Chief Accountant Gunta Kaufmane